Loading patent…
AssigneeSirna Therapeutics, Inc.
InventorsSteven Bartz, Duncan Brown, Michael Robinson
Estimating the term…
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of HBV gene expression and/or activity, and/or modulate a HBV gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against HBV gene expression.
A double-stranded short interfering nucleic acid (siNA) molecule comprising a sense strand comprising the nucleotide sequence 5′-B GCCgAUCCAUACUGCGGAAUsU B-3′ (SEQ ID NO:398) and an antisense strand comprising the nucleotide sequence 5′-UUCCGCAGUAUGGAUCGGCUsU-3′ (SEQ ID NO:248), wherein B is an inverted abasic moiety, bolded nucleotides comprise 2′-O-methyl modifications, lower case nucleotides comprise 2′-fluoro modifications, italicized nucleotides are deoxynucleotides, and s is a phosphorothioate linkage.
Dependencies are inferred from the claim text.